Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations
Cannabis & Cannabinoid Research · 01.04.2023 · 8 (2) · 254-269
DOI: 10.1089/can.2022.0133 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 30.03.2023. Verfasst von Abdel-Ilah Aziz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological and Medical Sciences, Mohammed VI Polytechnic University, Ben Guerir, Morocco. Hauptthemen laut MEDLINE: Cannabinoids, Cannabidiol, COVID-19, Cannabis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 195 Literaturangaben.
Abstract (Originalsprache)
Introduction
Cannabidiol (CBD) is the second most abundant Phytocannabinoid in Cannabis extracts. CBD has a binding affinity for several cannabinoid and cannabinoid-associated receptors. Epidiolex (oral CBD solution) has been lately licensed by the Food and Drug Administration (FDA) for the treatment of pediatric epileptic seizures.
Methods
In this review, we discussed the most promising applications of CBD for chronic inflammatory conditions, namely CBD's anti-inflammatory effects during inflammatory bowel disease, coronavirus disease (antiviral effect), brain pathologies (neuroprotective and anti-inflammatory properties), as well as CBD immunomodulatory and antitumoral activities in the tumor microenvironment. Special focus was shed on the main therapeutic mechanisms of action of CBD, particularly in the control of the immune system and the endocannabinoid system.
Results
Findings suggest that CBD is a potent immunomodulatory drug as it has manifested immunosuppressive properties in the context of sterile inflammation (e.g., inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases), and immunoprotective effects during viral infections (e.g. COVID-19) Similarly, CBD has exhibited a selective response toward cancer types by engaging different targets and signaling pathways. These results are in favor of the primary function of the endocannabinoid system which is homeostatic maintenance.
Conclusion
The presented evidence suggests that the endocannabinoid system is a prominent target for the treatment of inflammatory and autoimmune diseases, rheumatoid diseases, viral infections, neurological and psychological pathologies, and cancer. Moreover, the antitumoral activities of CBD have been suggested to be potentially used in combination with chemo- or immunotherapy during cancer. However, clinical results are still lacking, which raises a challenge to apply translational cannabis research to the human immune system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biological and Medical Sciences, Mohammed VI Polytechnic University, Ben Guerir, Morocco.
- Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois, USA.
- Onco-Dermatology and Therapies, INSERM UMRS976, Hôpital Saint Louis, Paris, France.
ORCID-Profile: Sanae Ben Mkaddem
Zitieren
APA
Aziz, A. I., Nguyen, L. C., Oumeslakht, L., Bensussan, A., & Ben Mkaddem, S. (2023). Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations. Cannabis & Cannabinoid Research, 8(2), 254-269. https://doi.org/10.1089/can.2022.0133
Vancouver
Aziz AI, Nguyen LC, Oumeslakht L, Bensussan A, Ben Mkaddem S. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations. Cannabis & Cannabinoid Research. 2023;8(2):254-269. doi:10.1089/can.2022.0133
BibTeX
@article{Aziz2023,
author = {Aziz, Abdel-Ilah and Nguyen, Long Chi and Oumeslakht, Loubna and Bensussan, Armand and Ben Mkaddem, Sanae},
title = {Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations},
journal = {Cannabis & Cannabinoid Research},
year = {2023},
volume = {8},
number = {2},
pages = {254--269},
doi = {10.1089/can.2022.0133}
}
EUVIMED